SSRI Selection for a 19-Year-Old with Moderate-Severe Depression and Self-Harm
Start with fluoxetine 10 mg daily or escitalopram 10 mg daily, as these are the only FDA-approved SSRIs for adolescents and young adults with depression, with fluoxetine having the broadest approval and escitalopram approved for ages 12 and older. 1
Initial SSRI Selection
Fluoxetine is the first-line choice as it is the only SSRI with FDA approval for children and adolescents with depression, starting at 10 mg daily with increments of 10-20 mg to an effective dose of 20 mg (maximum 60 mg). 1
Escitalopram is the alternative first-line option for patients 12 years and older, starting at 10 mg daily with 5 mg increments to an effective dose of 10 mg (maximum 20 mg). 1
Sertraline (25 mg starting dose) or citalopram (10 mg starting dose) are reasonable alternatives if fluoxetine or escitalopram are not tolerated, though they lack FDA approval for this age group. 1
Avoid paroxetine as it is specifically not recommended to be started in primary care settings for adolescents. 1
Critical Safety Considerations with Self-Harm Present
Start at the recommended low starting dose—never at higher doses—as deliberate self-harm and suicide risk are more likely to occur when SSRIs are initiated at higher than normal starting doses. 1
This patient's PHQ-9 score of 19 indicates moderately severe depression, and the presence of cutting behavior significantly elevates suicide risk, requiring intensive monitoring regardless of how the patient responds to PHQ-9 item 9 about thoughts of death or self-harm. 2, 3
Close monitoring is mandatory during the initial weeks of treatment per FDA black-box warning: observe closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial months and at times of dose changes. 1
Monitoring Protocol
Schedule contact (in-person or telephone) within 1 week of starting the SSRI to review understanding, adherence, current status, and screen for adverse events including behavioral activation, switch to mania, or increased suicide-related events. 1
Continue frequent monitoring for at least the first 18 months, as the elevated suicide risk associated with depression persists for this duration even with treatment. 2
Use a structured suicide risk assessment tool (such as the Columbia Suicide Severity Rating Scale) rather than relying solely on PHQ-9 item 9, which has poor specificity (66%) and positive predictive value (29%) for actual suicide risk, missing important clinical nuances. 3
Dosing Strategy
Support an adequate trial at the maximum tolerated dose and duration once the medication is tolerated, as effective dosages in adolescents are generally lower than adult guidelines but still require optimization. 1
Taper slowly when discontinuing any SSRI due to risk of withdrawal effects. 1
Common Pitfalls to Avoid
Do not delay SSRI initiation because the patient won't discuss precipitating events—the PHQ-9 score of 19 with self-harm behavior warrants pharmacotherapy alongside the newly initiated counseling. 1
Do not assume absence of suicidal ideation on screening means low risk—39% of suicide attempts and 36% of suicide deaths within 30 days of PHQ completion occurred among those responding "not at all" to item 9. 2
Ensure all MAOIs are contraindicated with any SSRI selection. 1